Effect of the alpha 2 adrenoreceptor antagonist, idazoxan, on motor disabilities in MPTP-treated monkey.
1. The motor effect of the alpha 2 adrenoreceptor antagonist, idazoxan, was compared to that of L-dopa in MPTP-treated monkeys. 2. Idazoxan 2.0 mg/kg improved parkinsonian motor abnormalities which was comparable to the effects of a minimal effective dose of L-dopa. 3. At 2.0 and 5.0 mg/kg, the parkinsonian rigidity was the item most frequently alleviated by idazoxan (respectively 63.6% and 68.2%). 4. These findings provide support for the therapeutic utility of alpha 2 antagonists in the treatment of Parkinson's disease.
Bezard
E
E
Laboratoire de Neurophysiologie, CNRS UMR 5543, Université de Bordeaux II, France.
Brefel
C
C
Tison
F
F
Peyro-Saint-Paul
H
H
Ladure
P
P
Rascol
O
O
Gross
C E
CE
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / Q000494:pharmacology*; D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology*; D000818:Animals; D004195:Disease Models, Animal; D015259:Dopamine Agents / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D005260:Female; D019329:Idazoxan / Q000494:pharmacology*; D008252:Macaca fascicularis; D019957:Motor Skills Disorders / Q000139:chemically induced* / Q000188:drug therapy; D010300:Parkinson Disease / Q000188:drug therapy
D000317:Adrenergic alpha-Antagonists; D015259:Dopamine Agents; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D019329:Idazoxan